2cureX terminates liquidity provision service - Börskollen
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

•Kom igång: Så börjar du spara i fonder 2025 – bästa tipsen för att komma igång (stor guide)

Pressmeddelande

2cureX terminates liquidity provision service

MFN Publicerad: 29 Sep 2022 21:00
2cureX

2curex announces today that it has terminated the liquidity provision service that was being offered on the company’s share.
 
The service was initiated in May 2022 to promote a good liquidity in the share and ensure a low spread between the bid and ask price in current trading.
 
We consider that under the current market circumstances, the intended benefit is not being perceived, thus the decision to stop the service. We will continue, as always, to explore any tools that might help our shareholders and interested investors.

About 2cureX

2cureX is a leader in cancer drug sensitivity testing and has developed the IndiTreat® (Individual Treatment) family of tests. Starting from a sample of the patient’s tumor, IndiTreat® creates thousands of 3D replicas (tumoroids) and predicts the tumor response to the different available drugs, providing the physician with valuable information to make the treatment decisions.

The first three IndiTreat® tests are aimed at optimizing treatment decisions in patients with metastatic colorectal cancer (IndiTreat® Start for first line of therapy, IndiTreat® Extend and Explore for third line). Additional tests are under development to cover other stages of colorectal cancer as well as other gastrointestinal cancers.

According to several reports, the total yearly expenditure in cancer-related In Vitro Diagnostic (IVD) tests exceeds 17.5Bn USD worldwide, from which 2.5 Bn USD are tests directly related to therapy decision making, with a CAGR of 12.7%. Despite this, only one third of all cancer treatments are supported by one of these tests. IndiTreat® aims at filling this gap and making Precision Oncology available to all cancer patients.

The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). For more information about 2cureX visit www.2cureX.com
 
Certified Adviser: Redeye AB, +46 8 121 576 90, [email protected]

Attachments

2cureX terminates liquidity provision service

Bifogade filer

2cureX terminates liquidity provision servicehttps://storage.mfn.se/432a4bc4-21e4-49b1-8681-15e9d2395984/2curex-terminates-liquidity-provision-service.pdf

Nyheter om 2cureX

Läses av andra just nu

Om aktien 2cureX

Senaste nytt